Revolo Biotherapeutics Presents New Data Demonstrating Long-Lasting Effect of ‘1104 in a Food Allergy Model at the 2023 AAAAI Annual Meeting NEW ORLEANS and CAMBRIDGE, United Kingdom, Feb. 28, 2023 (GLOBE NEWSWIRE) -...
Sanofi will present 24 abstracts, including four oral presentations and a late-breaking poster, across approved and investigational medicines at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting in San Diego, CA from February 28 – March 3, 2025. Presentations in ...
Pharvaris today announced a poster detailing positive data from its Phase 2 RAPIDe-1 study of PHVS416 for the on-demand treatment of attacks will be presented at the American Academy of Allergy Asthma & Immunology (AAAAI) Annu...
During theAmerican Academy of Allergy, Asthma & Immunology (AAAAI) 2023 Annual Meeting, new research was presented on the potential advantages of treating early symptoms or prodromes of hereditary angioedema (HAE) to prevent acute attacks. Results emphasized the significance of ...
This interactive meeting will include ample opportunities to network and explore groundbreaking, basic science research within the allergy/immunology specialty while showcasing the efforts of junior investigators through selected short talks, poster Support Young Investigators with the GAIN Campaign The GAIN ...
Deadline to claim credit for the 2023 Annual Meeting February 23-26, 2024 Annual Meeting in Washington DC 注册费: Registration Types We are pleased to announce that the 2024 AAAAI Annual Meeting will include the option to attend either virtually or in person. Our educational programming includes...
Early-life day care attendance may be protective against allergen sensitization, according to a study presented at the annual meeting of the American Academy of Allergy, Asthma & Immunology, held from Feb. 23 to 26 in Washington, D.C.
Kinaset Therapeutics today announced an upcoming oral presentation at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting being held on February 23-26, 2024.
Blueprint Medicines Corporation (NASDAQ: BPMC) today announced plans to present detailed results from the registrational PIONEER trial of AYVAKIT® (avapritinib) in indolent systemic mastocytosis (SM) at the 2023 American Academ...